

**Effects on the liver.** The UK MHRA had warned<sup>1</sup> that there had been cases of hepatotoxicity associated with adulteration of traditional Chinese slimming medicines with fenfluramine and/or nitrofenfluramine. Nitrofenfluramine was known to be hepatotoxic.

1. Medicines and Healthcare products Regulatory Agency (MHRA). Shubao slimming capsules containing fenfluramine and nitrofenfluramine (issued 28th April, 2004). Available at: <http://www.mhra.gov.uk/home/groups/es-herbal/documents/websteresources/con009291.pdf> (accessed 11/08/08)

**Porphyria.** Fenfluramine is considered to be unsafe in patients with porphyria because it has been shown to be porphyrinogenic in animals.

## Uses and Administration

Fenfluramine is an indirect-acting sympathomimetic related to amphetamine, but at standard doses it usually depresses rather than stimulates the CNS. It appears to stimulate the release of serotonin and selectively inhibits its reuptake resulting in increased CNS serotonin concentrations. It may also increase glucose utilisation and lower blood-glucose concentrations.

Fenfluramine was formerly given by mouth as the hydrochloride in the treatment of obesity (p.2149) but was generally withdrawn worldwide after reports of valvular heart defects.

## Preparations

**Proprietary Preparations** (details are given in Part 3)

**Chile:** Megavalf.


## Fenproporex Hydrochloride (rINN) ⊗

N-2-Cyanoethylamphetamine Hydrochloride; Fenproporex, Chlorhydrate de; Fenproporexi Hydrochloridum; Hidrocloruro de fenproporex. (±)-3-(α-Methylphenethylamino)propionitrile hydrochloride.

Фенпропорекса Гидрохлорид

C<sub>12</sub>H<sub>16</sub>N<sub>2</sub>.HCl = 224.7.

CAS — 15686-61-0 (fenproporex); 18305-29-8 (fenproporex hydrochloride).



NOTE. The following terms have been used as 'street names' (see p.vi) or slang names for various forms of fenproporex: Pasexes.

## Profile

Fenproporex is a central stimulant and indirect-acting sympathomimetic with actions similar to those of dexamfetamine (p.2153). After oral doses it is reported to be metabolised to amphetamine. Fenproporex has been given as the hydrochloride, the diphenylacetate, and as a resin.

Fenproporex hydrochloride has been used as an anorectic in the treatment of obesity (p.2149) although the use of stimulants in this way is no longer recommended. Regulatory authorities in the EU have called for the withdrawal of all anorectics from the market (see under Effects on the Cardiovascular System in Fenfluramine, p.2156).

## Preparations

**Proprietary Preparations** (details are given in Part 3)

**Braz:** Desobesi-M; Lipomax†; **Chile:** Salca; Sinapet†; **Mex:** Feprorex; Ifa-Diety.

**Multi-ingredient:** **Arg:** Tratotbes; **Mex:** Esbelcaps.


## Lisdexamfetamine Mesilate (rINN) ⊗

Lisdexamfetamine Dimesylate (USAN); Lisdeksamfetamine, Mésilate de; Lisdeksamfetamini Mesilas; Mesilato de lisdeksamfetamina; NRP-104. (2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate.

Лисдеksamфетамин Мезилат

C<sub>15</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub>(CH<sub>3</sub>SO<sub>2</sub>)<sub>2</sub> = 455.6.

CAS — 608137-32-2 (lisdexamfetamine); 608137-33-3 (lisdexamfetamine mesilate).



## Profile

Lisdexamfetamine is a prodrug of dexamfetamine (p.2153). It is used as a central stimulant in the treatment of attention deficit hyperactivity disorders (p.2148).

Lisdexamfetamine is given orally as the mesilate and doses are expressed in terms of this salt. For adults, and children between 6 and 12 years of age, the starting dose is 30 mg once daily in the morning, increased if necessary in increments of 10 or 20 mg daily at approximately weekly intervals, up to a total maximum dose of 70 mg daily. If therapy is continued for longer than 4 weeks, use of lisdexamfetamine should be periodically stopped to evaluate the necessity for continued administration.

## References

- Blick SK, Keating GM. Lisdexamfetamine. *Paediatr Drugs* 2007; **9**: 129–35.
- Biederman J, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. *Clin Ther* 2007; **29**: 450–63.

## Preparations

**Proprietary Preparations** (details are given in Part 3)

**USA:** Vyvanse.

## Lobelia

Indian Tobacco.

**Description.** Lobelia consists of the dried aerial parts of *Lobelia inflata* (Lobeliaceae). Lobeline is the main alkaloidal constituent.


## Lobeline Hydrochloride (BANM, rINN) ⊗

Alpha-lobeline Hydrochloride; Hidrocloruro de lobelina; Lobeliinihydrokloridi; Lobéline, chlorhydrate de; Lobelin-hidroklorid; Lobelin-hydrochlorid; Lobelinhydroklorid; Lobelini hydrochloridum; Lobelino hydrochloridas. 2-[6-(β-Hydroxyphenethyl)-1-methyl-2-piperidyl]acetophenone hydrochloride.

Лобелина Гидрохлорид

C<sub>22</sub>H<sub>27</sub>NO<sub>2</sub>.HCl = 373.9.

CAS — 90-69-7 (lobeline); 134-63-4 (lobeline hydrochloride).



**Pharmacopoeias.** In *Chin.* and *Eur.* (see p.vii).

**Ph. Eur. 6.2** (Lobeline Hydrochloride). A white or almost white microcrystalline powder. Sparingly soluble in water; freely soluble in alcohol; soluble in dichloromethane. A 1% solution in water has a pH of 4.6 to 6.4. Protect from light.

## Lobeline Sulfate (rINN) ⊗

Lobéline, Sulfate de; Lobeline Sulphate (BANM); Lobelini Sulfas; Sulfato de lobelina.

Лобелина Сульфат

(C<sub>22</sub>H<sub>27</sub>NO<sub>2</sub>)<sub>2</sub>.H<sub>2</sub>SO<sub>4</sub> = 773.0.

CAS — 134-64-5.

## Adverse Effects

Adverse effects of lobelia and lobeline include nausea and vomiting, coughing, tremor, and dizziness. Symptoms of overdose include profuse diaphoresis, paresthesia, tachycardia, hypothermia, hypotension, and coma; fatalities have occurred.

## Uses and Administration

Lobelia is the dried aerial parts of *Lobelia inflata* (Lobeliaceae). Lobeline is the main alkaloidal constituent and has peripheral and central effects similar to those of nicotine (p.2352).

Lobelia has been used mainly in preparations aimed at relieving respiratory-tract disorders. Lobeline has been given by mouth as the hydrochloride or sulfate as a smoking deterrent (see Smoking Cessation, p.2354). Lobelia has been used similarly given either orally or incorporated into herbal cigarettes.

**Smoking cessation.** Reviews of smoking cessation therapy generally consider lobeline to have little benefit compared with placebo.<sup>1-3</sup>

- Nunn-Thompson CL, Simon PA. Pharmacotherapy for smoking cessation. *Clin Pharm* 1989; **8**: 710–20.

- Gourlay SG, McNeil JJ. Antismoking products. *Med J Aust* 1990; **153**: 699–707.

- Stead LF, Hughes JR. Lobeline for smoking cessation. Available in The Cochrane Database of Systematic Reviews; Issue 3. Chichester: John Wiley; 1997 (accessed 16/05/05).

## Preparations

**Proprietary Preparations** (details are given in Part 3)

**Austral:** Cig-Ridettes†; **Canad:** Butt-Out; **Spain:** Smokeless.

**Multi-ingredient:** **Austral:** Potassium Iodide and Stramonium Compound†; **Belg:** Kamfeine†; **Braz:** Asmatron†; Bronquidex; Brontoss; Expectobron†; Expectol†; Iodeto de Potasio†; Iof†; Iolint†; MM Expectante; Pulmoforte†; Sedatux†; Xarope Peitoral de Ameixa Composto†; **Chile:** Paltomiel Plus; Pulmagol; Ramitoss; **Spain:** Pazbronquial; **UK:** Antibron; Asthma & Catarrh Relief; Balm of Gilead; Chest Mixture; Herbelco; Horehound and Aniseed Cough Mixture; Modern Herbals Cold & Congestion; Vegetable Cough Remover; **Venez:** Novacodin.

## Mazindol (BAN, USAN, rINN) ⊗

42-548; AN-448; Matsindol; Mazindolum; SaH-42548. 5-(4-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol.


Мазиндол

C<sub>16</sub>H<sub>13</sub>ClN<sub>2</sub>O = 284.7.

CAS — 22232-71-9.

ATC — A08AA05.

ATC Vet — QA08AA05.



**Pharmacopoeias.** In *US*.

**USP 31** (Mazindol). A white to off-white crystalline powder, having not more than a faint odour. Insoluble in water; slightly soluble in chloroform and in methyl alcohol. Store in airtight containers.

## Adverse Effects, Treatment, and Precautions

As for Dexamfetamine Sulfate, p.2153.

**Effects on the testes.** Testicular pain developed in 8 men after taking mazindol.<sup>1</sup>

- McEwen J, Meyboom RHB. Testicular pain caused by mazindol. *BMJ* 1983; **287**: 1763–4.

## Interactions

As for Dexamfetamine Sulfate, p.2153.

**Lithium.** For a report of mazindol interacting with lithium to cause lithium toxicity, see Central Stimulants, p.405.

## Pharmacokinetics

Mazindol is readily absorbed from the gastrointestinal tract and is excreted in the urine, partly unchanged and partly as metabolites.

## Uses and Administration

Mazindol is a central stimulant with actions similar to those of dexamfetamine (p.2154), although structurally the two compounds are unrelated. It appears to inhibit reuptake of dopamine and noradrenaline. It has been used as an anorectic, given orally in the treatment of obesity (p.2149), although stimulants are no longer recommended for this indication. Regulatory authorities in the EU have called for the withdrawal of all anorectics from the market (see under Effects on the Cardiovascular System in Fenfluramine, p.2156).

Mazindol has been investigated in the treatment of Duchenne muscular dystrophy.

**Narcolepsy.** Mazindol has been reported<sup>1-4</sup> to be beneficial in patients with narcolepsy and associated cataplexy (p.2148). A wide range of doses has been used: 3 to 8 mg daily in one study,<sup>1</sup> 1 mg weekly to 16 mg daily in another,<sup>3</sup> children have been given 1 to 2 mg daily.<sup>4</sup>

- Parkes JD, Schachter M. Mazindol in the treatment of narcolepsy. *Acta Neurol Scand* 1979; **60**: 250–4.
- Shindler J, et al. Amphetamine, mazindol, and fencamfamin in narcolepsy. *BMJ* 1985; **290**: 1167–70.
- Alvarez B, et al. Mazindol in long-term treatment of narcolepsy. *Lancet* 1991; **337**: 1293–4.
- Allsopp MR, Zaiwalla Z. Narcolepsy. *Arch Dis Child* 1992; **67**: 302–6.

## Preparations

**USP 31:** Mazindol Tablets.

**Proprietary Preparations** (details are given in Part 3)

**Arg:** Afilar; Dimagrin; Dimagrin Triac†; Fagolip Plus; Samonter; **Braz:** Absten S; Fagolip; **Canad:** Sanorex†; **Hong Kong:** Qualizindol; **Hung:** Tonac†; **Indon:** Teronac; **Mex:** Diestet; Ifa Lose; Ilezol; Liolindol†; Obendol; Sanorex†; Solucaps; **Singapore:** Teronac; **Switz:** Teronac†.

**Multi-ingredient:** **Arg:** Maxiratobes; **Braz:** Dobesix†; Moderine.

